HUP0301122A3 - Pharmaceutical combinations and their use in treating gastrointestinal disorders - Google Patents

Pharmaceutical combinations and their use in treating gastrointestinal disorders

Info

Publication number
HUP0301122A3
HUP0301122A3 HU0301122A HUP0301122A HUP0301122A3 HU P0301122 A3 HUP0301122 A3 HU P0301122A3 HU 0301122 A HU0301122 A HU 0301122A HU P0301122 A HUP0301122 A HU P0301122A HU P0301122 A3 HUP0301122 A3 HU P0301122A3
Authority
HU
Hungary
Prior art keywords
gastrointestinal disorders
pharmaceutical combinations
treating gastrointestinal
treating
pharmaceutical
Prior art date
Application number
HU0301122A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0301122A2 publication Critical patent/HUP0301122A2/hu
Publication of HUP0301122A3 publication Critical patent/HUP0301122A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
HU0301122A 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders HUP0301122A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45838899A 1999-12-10 1999-12-10
PCT/EP2000/012420 WO2001041748A2 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Publications (2)

Publication Number Publication Date
HUP0301122A2 HUP0301122A2 (hu) 2003-08-28
HUP0301122A3 true HUP0301122A3 (en) 2005-03-29

Family

ID=23820591

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0301122A HUP0301122A3 (en) 1999-12-10 2000-12-08 Pharmaceutical combinations and their use in treating gastrointestinal disorders

Country Status (30)

Country Link
EP (3) EP1286668B1 (https=)
JP (1) JP2003523324A (https=)
KR (1) KR100765579B1 (https=)
CN (2) CN1875966A (https=)
AR (1) AR026916A1 (https=)
AT (1) ATE293971T1 (https=)
AU (2) AU778869B2 (https=)
BR (1) BR0016275A (https=)
CA (1) CA2388959A1 (https=)
CO (1) CO5261535A1 (https=)
CZ (1) CZ300690B6 (https=)
DE (1) DE60019814T2 (https=)
DK (1) DK1286668T3 (https=)
ES (1) ES2240229T3 (https=)
HU (1) HUP0301122A3 (https=)
IL (2) IL149496A0 (https=)
MX (1) MXPA02005695A (https=)
MY (1) MY133423A (https=)
NO (1) NO20022680L (https=)
NZ (2) NZ531489A (https=)
PE (1) PE20011030A1 (https=)
PL (1) PL202201B1 (https=)
PT (1) PT1286668E (https=)
RU (1) RU2264215C2 (https=)
SG (1) SG152025A1 (https=)
SK (1) SK8062002A3 (https=)
TR (1) TR200402293T2 (https=)
TW (1) TWI263496B (https=)
WO (1) WO2001041748A2 (https=)
ZA (1) ZA200204493B (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001261606A1 (en) * 2000-05-18 2001-11-26 Glaxo Group Limited Method for treating functional dyspepsia
GB0209481D0 (en) * 2002-04-24 2002-06-05 Novartis Ag Organic compounds
NZ541009A (en) 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating nausea, vomiting, retching or any combination thereof
GB0307440D0 (en) * 2003-03-31 2003-05-07 Novartis Ag Organic compounds
JP2006528231A (ja) * 2003-05-27 2006-12-14 アルタナ　ファルマ　アクチエンゲゼルシャフト プロトンポンプ阻害剤と胃腸運動性を変更する化合物との医薬品組合せ物
US20050090554A1 (en) * 2003-09-12 2005-04-28 John Devane Treatment of gastroparesis and nonulcer dyspepsia with GABAB agonists
US7820690B2 (en) 2004-03-19 2010-10-26 Solvay Pharmaceuticals Gmbh Method of treating or inhibiting a non-digestive tract derived abdominal disorder associated with pain using a 5-HT, receptor antagonist
RU2007105346A (ru) * 2004-07-14 2008-09-27 Новартис АГ (CH) Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы
MX2007009136A (es) * 2005-01-31 2007-09-06 Novartis Ag Uso de agonista de 5-ht4 para tratar vacio gastrico retrasado que puede inducirse por un inhibidor de bomba de protones.
GB0506800D0 (en) * 2005-04-04 2005-05-11 Merck Sharp & Dohme New uses
US8324192B2 (en) 2005-11-12 2012-12-04 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
US8679545B2 (en) 2005-11-12 2014-03-25 The Regents Of The University Of California Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
JP2009525269A (ja) 2006-01-30 2009-07-09 ユーロ−セルティーク エス．エイ． カルシウムチャネルブロッカーとしての環状尿素化合物
RU2008152196A (ru) * 2006-06-15 2010-07-20 Новартис АГ (CH) Композиции, включающие тегасерод в отдельности или в комбинации с ингибитором протонного насоса, для лечения или профилактики повреждений желудочно-кишечного тракта
KR20090107088A (ko) 2007-02-09 2009-10-12 트랜자임 파르마 인크 거대고리 그렐린 수용체 조절제 및 이의 사용 방법
EP2214679B1 (en) 2007-11-13 2019-03-27 Meritage Pharma, Inc. Corticosteroid compositions
US20090143343A1 (en) 2007-11-13 2009-06-04 Meritage Pharma, Inc. Compositions for the treatment of inflammation of the gastrointestinal tract
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
US20220396623A1 (en) 2021-05-18 2022-12-15 Kymab Limited Uses of anti-icos antibodies
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer
US20250340641A1 (en) 2022-05-18 2025-11-06 Kymab Limited Uses of anti-icos antibodies
FR3144752A1 (fr) 2023-01-10 2024-07-12 Song Huang Utilisation de polysulfate de pentosane pour le traitement de la toux seche

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362756A (en) * 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
EP0617620B1 (en) * 1991-12-21 1998-09-09 Smithkline Beecham Plc Use of 5-ht4 - antagonists for the manufacture of a medicament for the treatment of urinary incontinence
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
DK0794184T3 (da) * 1994-11-21 2001-07-30 Dainippon Pharmaceutical Co 6-Methoxy-1H-benzotriazol-5-carboxamidderivater, fremgangsmåde til fremstilling deraf og lægemidler indeholdende dem
US5919760A (en) * 1996-04-12 1999-07-06 Intensive Narcotic Detoxification Centers Of America, Llc Method for treating acute and severe diarrhea
US6156771A (en) * 1997-08-28 2000-12-05 Rubin; Walter Method for alleviation of lower gastrointestinal disorders in a human patient
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
SG152025A1 (en) 2009-05-29
AU2005200797A1 (en) 2005-03-17
AU2672801A (en) 2001-06-18
TWI263496B (en) 2006-10-11
HUP0301122A2 (hu) 2003-08-28
NZ566800A (en) 2009-11-27
CN1409634A (zh) 2003-04-09
CZ20021967A3 (cs) 2002-08-14
TR200402293T2 (tr) 2004-10-21
CN1875966A (zh) 2006-12-13
MXPA02005695A (es) 2002-09-18
NO20022680L (no) 2002-08-12
NZ531489A (en) 2005-09-30
PE20011030A1 (es) 2001-10-31
SK8062002A3 (en) 2003-04-01
PL202201B1 (pl) 2009-06-30
KR100765579B1 (ko) 2007-10-09
PL355663A1 (en) 2004-05-04
DE60019814D1 (de) 2005-06-02
EP1488788A1 (en) 2004-12-22
CA2388959A1 (en) 2001-06-14
CO5261535A1 (es) 2003-03-31
EP1286668B1 (en) 2005-04-27
DK1286668T3 (da) 2005-08-15
RU2264215C2 (ru) 2005-11-20
ATE293971T1 (de) 2005-05-15
WO2001041748A2 (en) 2001-06-14
IL149496A0 (en) 2002-11-10
JP2003523324A (ja) 2003-08-05
AR026916A1 (es) 2003-03-05
WO2001041748A3 (en) 2002-12-19
NO20022680D0 (no) 2002-06-06
BR0016275A (pt) 2002-08-27
CN1310644C (zh) 2007-04-18
KR20030016208A (ko) 2003-02-26
RU2002118316A (ru) 2004-02-20
ZA200204493B (en) 2003-09-29
ES2240229T3 (es) 2005-10-16
AU778869B2 (en) 2004-12-23
IL149496A (en) 2009-12-24
PT1286668E (pt) 2005-08-31
AU2005200797B2 (en) 2008-01-24
MY133423A (en) 2007-11-30
EP1286668A2 (en) 2003-03-05
DE60019814T2 (de) 2006-03-02
CZ300690B6 (cs) 2009-07-15
EP1913944A1 (en) 2008-04-23

Similar Documents

Publication Publication Date Title
IL149496A0 (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
AU2001293553A1 (en) Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment
EP0924983A4 (en) S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
IL156678A0 (en) Glucopyranosyloxypyrazole derivatives and use thereof in medicines
IL144954A0 (en) Quinazolines and therapeutic use thereof
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0203430A3 (en) Quinazolinones and their use
GB9721437D0 (en) Heteroaromatic compounds and their use in medicine
HUP0400069A3 (en) Pharmaceutical combinations and their use in preventing and treating the thrombosis
SI1143997T1 (en) Tumor necrosis factor antagonists and their use in endometriosis treatment
AU2002243363A8 (en) Use of aziridino-compounds in the treatment of immune dysfunctions
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
CZ20021489A3 (cs) N-guanidinoalkylamidy, jejich příprava, pouľití a farmaceutické směsi, které je obsahují
AU2001266229A1 (en) Hcn polypeptides and polynucleotides and their use in therapy
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
PL363048A1 (en) Azabicyclic derivatives and their therapeutic use
HUP0105351A3 (en) Effervescent laxatives and their use
SI1286668T1 (en) Pharmaceutical combinations comprising tegaserod und omeprazole and their use in treating gastrointestinal disorders
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
HUP0105203A3 (en) S-nitrosothiols as agents for the treatment of circulatory dysfunctions and their use
GB9929581D0 (en) Comjpositions and their use
GB9903919D0 (en) Aminophenols and their therapeutic use
HUP0201800A2 (en) Novel calpains and their use
HUP9900045A3 (en) Improved leukaemic blood-based product and their use in therapy
GB0026428D0 (en) Hydroimidazolone derivatives and their use in therapy

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees